Skip to main content
. 2023 Aug 2;8(9):853–858. doi: 10.1001/jamacardio.2023.2222

Figure 1. Primary End Point According to Assigned Treatment in Very High-Risk (VHR) and Non-VHR Patients With Atherosclerotic Cardiovascular Disease (ASCVD).

Figure 1.

The cumulative incidences of the primary end point at 3 years after randomization (intention-to-treat population) comparing moderate-intensity statin with ezetimibe combination vs high-intensity statin monotherapy in VHR and non-VHR patients. The interaction P value shows no evidence of significant heterogeneity for the treatment outcomes of the primary endpoint among VHR and non-VHR. HR indicates hazard ratio.